Overview
Graduate Program
Academic Events
Reservation

Overview

Laboratory Introduction

Laboratory of Cancer Hematogenomics

Laboratory of Cancer Hematogenomics
Our laboratory opened in 2001 at Samsung Cancer Research Institute. Led by Professor Sung-Soo Yoon, our laboratory is actively conducting collaborative research with domestic and researchers abroad. Our research aims at better understanding and treatment of hematologic malignancies.
Related Researcher
고영일

Youngil Koh Professor

Research topics

유전체·전사체 분석, 유전자 조작 세포 및 동물 모델 구축, 면역치료 및 세포치료 기술 개발, 신약 반응성 평가 등 다양한 접근법을 통해 기초 연구부터 임상 적용까지 연결되는 연구를 진행하고 있다.

Research Areas

1. Genome Engineering and Cell Therapy

  • CRISPR/Cas9 기반 정밀 유전자 편집 (Knock-out / Knock-in) 기술 개발

  • AAV / Nanoplasmid 기반 유전자 치료 플랫폼 개발

  • Allogeneic CAR-T 세포 치료제 설계 및 기능 최적화

2. Clonal Hematopoiesis and Blood Cancer Biology

  • DNMT3A, TET2 등 clonal hematopoiesis 관련 돌연변이의 병리 기전 규명

  • 클론성 조혈이 암 발생 및 면역 환경에 미치는 영향 분석

  • CHIP 기반 신규 치료 타겟 발굴

3. Functional Genomics and Therapeutic Target Discovery

  • 혈액암 세포주 및 환자 유래 샘플 기반 약물 반응성 및 작용기전 분석

  • 유전자 knock-down / overexpression 모델을 통한 기능 연구

  • 동물 모델을 이용한 표적치료제 및 면역치료제 효능 평가

4. Multi-Omics and Computational Biology

  • WGS/WES 기반 암 발생 기전 분석

  • TCGA, ICGC, UK Biobank 데이터 통합 분석

  • Single-cell omics 기반 바이오마커 발굴

Research Expansion

  • 혈액암 연구 기반으로 신장질환, 간질환, 염증성 질환 등 다양한 질환으로 연구 확장

Research goals
A step towards precision medicine: We aim to better understand and ultimately provide innovative treatment options for blood cancers through comprehensive analyses of blood cell lines and patients' samples.
Research achievements

2026
Koh Y, Tengesdal IW, Jaiswal S. Clonal Hematopoiesis in Nonmalignant Disease: Functional Consequences of Mutated Immune Cells in the Diseased Tissue. Annu Rev Pathol. 21(1):19-36.

2025
Lee D, Koo B, Kim S, et al. Increased local DNA methylation disorder in AMLs with DNMT3A-destabilizing variants and its clinical implication. Nat Commun. 16:560.


2024
Chun C, Byun JM, Cha M, et al. Profiling protein–protein interactions to predict the efficacy of BCL-2-homology-3 mimetics for acute myeloid leukaemia. Nat Biomed Eng. 8:1379-1395.

Ahn HY, An HY, Ryu G, et al. Clonal haematopoiesis of indeterminate potential and atrial fibrillation: an east Asian cohort study. Eur Heart J. 45(10):778-790.

Park C, Lee HS, Kang KW, et al. Combination of acalabrutinib with lenalidomide and rituximab in relapsed/refractory aggressive B-cell non-Hodgkin lymphoma: a single-arm phase II trial. Nat Commun. 15(1):2776.

Lee G, Lee SM, Lee S, et al. Prediction of metabolites associated with somatic mutations in cancers by using genome-scale metabolic models and mutation data. Genome Biol. 25(1):66.

2023
Liu J, Min S, Kim D, et al. Pharmacological GLUT3 salvage augments the efficacy of vitamin C-induced TET2 restoration in acute myeloid leukemia. Leukemia. 37:1638-1648.

Wang ML, et al. (Koh Y participating). Pirtobrutinib in Covalent BTK Inhibitor Pretreated Mantle-Cell Lymphoma. J Clin Oncol. 41:3988-3997.

Prior Key Publications
Moreau P, Dimopoulos MA, ..., Koh Y, et al. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. Lancet. 2021;397(10292):2361-2371.

Bolton K, Koh Y, Foote M, et al. Clonal hematopoiesis is associated with risk of severe Covid-19. Nat Commun. 2021;12(1):5975.

Photos
List